A U.S. volunteer became the first person to receive an experimental COVID-19 vaccine as part of the first phase of humans trial on March 16, the Associated Press reports.
For story suggestions or custom animation requests, contact tips@nextanimation.com.tw.
Visit http://archive.nextanimationstudio.com to view News Direct's complete archive of 3D news animations.
RESTRICTIONS: Broadcast: NO USE JAPAN, NO USE TAIWAN Digital: NO USE JAPAN, NO USE TAIWAN A U.S. volunteer became the first person to receive an experimental COVID-19 vaccine as part of the first phase of humans trial on March 16, the Associated Press reports.
According to Kaiser Permanente, which is funded by the National Institutes of Health to conduct the project, the vaccine eschews dead or inert viruses and instead utilizes messenger RNA, or mRNA.
A previous study in Molecular Theory suggests engineered mRNA could cause ribosomes in human cells to manufacture artificially designed proteins.
According to Kaiser Permanente, their vaccine would make cells produce a protein that is found in the outer coating of SARS-CoV-2, which triggers an immune response.
If a person who received the vaccine is later infected with COVID-19, their prior immune response may help their body mount a stronger reaction to the real virus infection.
RUNDOWN SHOWS: 1.
Kaiser Permanente tests experimental COVID-19 vaccine on first volunteer 2.
Messenger RNA vaccine makes cells produce viral proteins 3.
Viral protein triggers immune response 4.
Prior immune response is then expected to strengthen immune reaction to COVID-19 VOICEOVER (in English): "A U.S. volunteer became the first person to receive an experimental COVID-19 vaccine as part of the first phase of humans trial on March 16, the Associated Press reports." "According to Kaiser Permanente, which is funded by the National Institutes of Health to conduct the project, the vaccine eschews dead or inert viruses and instead utilizes messenger RNA, or mRNA." "A previous study in Molecular Theory suggests engineered mRNA could cause ribosomes in human cells to manufacture artificially designed proteins." "According to Kaiser Permanente, their vaccine would make cells produce a protein that is found in the outer coating of SARS-CoV-2, which triggers an immune response." "If a person who received the vaccine is later infected with COVID-19, their prior immune response may help their body mount a stronger reaction to the real virus infection." SOURCES: National Institutes of Health, Associated Press, Kaiser Permanente, Molecular Therapy, Live Science https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins https://apnews.com/76b614811eef32955180c8260188bc24 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(19)30088-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1525001619300887%3Fshowall%3Dtrue https://www.livescience.com/first-person-coronavirus-vaccine-clinical-trial.html *** For story suggestions please contact tips@nextanimation.com.tw For technical and editorial support, please contact: Asia: +61 2 93 73 1841 Europe: +44 20 7542 7599 Americas and Latam: +1 800 738 8377
A hospital in Houston is the first in the country to be approved by the FDA to give critically ill COVID-19 patients plasma from..
